Alzheimer's disease: A molecular mechanism, new hypotheses, and therapeutic strategies;Alzheimerio liga: Molekulinis mechanizmas, naujos hipotezės, gydymo perspektyvos

Medicina

Volumn 46, Issue 1, 2010, Pages 70-76

  Plečkaityte, Milda ^a  

^a Institute of Biotechnology   (Lithuania)

Author keywords

Alzheimer's disease; Amyloid protein; Fibrils; Oligomers; Protein folding

Indexed keywords

AMYLOID BETA PROTEIN; CHAPERONE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALZHEIMER DISEASE; ANIMAL; DISEASE MODEL; GENETICS; GENOTYPE; HUMAN; METABOLISM; MORTALITY; MOUSE; MUTATION; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHENOTYPE; PROTEIN FOLDING; RANDOMIZED CONTROLLED TRIAL; REVIEW; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; GENOTYPE; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR CHAPERONES; MUTATION; PHENOTYPE; PROTEIN FOLDING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77953030300     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina46010011     Document Type: Article

References (44)

1. Klein WL. Cytotoxic intermediates in the fibrillation pathway: A( oligomers in Alzheimer's disease as a case study. In: Uvertsky VN, Fink AL, editors. Protein misfolding, aggregation, and conformational diseases. Part A: Protein aggregation and conformational diseases. New York: Springer; 2006. p. 61-75.
2. Sekoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66.
3. Hartl FU, Hayer-Hartl M. Converging concepts of protein folding in vitro and in vivo. Nat Struct Mol Biol 2009;16: 574-81.
4. Sherman MY, Goldberg AL. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001;29:15-32.
5. Macario AJ, Conway de Macario E. Sick chaperones, cellular stress, and disease. N Engl J Med 2005;353:1489-501.
6. Muchovski PJ. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperone. Neuron 2002;35:9-12.
7. Amrani M, Allen NJ, O'Shea J, Corbett J, Dunn MJ, Tadjkarimi S, et al. Role of catalase and heat shock protein on recovery of cardiac endothelial and mechanical function after ischemia. Cardioscience 1993;4:193-8.
8. Glener GG, Wong CW. Alzheimer's disease: initial report of the purification and characterization of a novel cerebro-vascular amyloid protein. Biochem Biophys Res Commun 1984;120:885-90.
9. Henriques AG, Vieira SI, Rebelo S, Domingues SC, da Cruz e Silva EF, da Cruz e Silva OA. Isoform specific amyloid-beta protein precursor metabolism. J Alzheimers Dis 2007; 11:85-95.
10. da Cruz e Silva EF, da Cruz e Silva OA. Protein phosphorylation and APP metabolism. Neurochem Res 2003;28:1553-61.
11. Walsh DM, Minogue AM, Sala Frigerio C, Fadeeva JV, Wasco W, Selkoe DJ. The APP family of proteins: similarities and differences. Biochem Soc Trans 2007;35:416-20.
12. Chartie-Harlin MC, Crawford F, Houlden H, Warren A. Hughes D, Fidani L, et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. Nature 1991;353:844-6.
13. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 1995;376: 775-8.
14. Hardy J. The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci USA 1997;94:2095-7.
15. Vetrivel KS, Zhang YW, Xu H, Thinakaran G. Pathological and physiological functions of presenilins. Mol Neurodegener 2006;1:4.
16. Wakabayashi T, De Strooper B. Presenilins: members of the γ-secretase quartets, but part-time soloists too. Physiology 2009;23:194-204.
17. Walsh DM, Selkoe DJ. Aβ oligomers a decade of discovery. J Neurochem 2007;101:1172-2284.
18. Busciglio J, Lorenzo A, Yankner B. Methodological variables in the assessment of beta-amyloid neurotoxicity. Neurobiol Aging 1992;13:609-12.
19. Kirschner DA, Inouye H, Duffy LK, Sinclair A, Lind M, Selkoe DJ. Synthetic peptide homologous to beta protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci USA 1987;84(19):6953-7.
20. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256:184-5.
21. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23:138-44.
22. Terry RD. Neuropathological changes in Alzheimer's disease. Prog Brain Res 1994;101:383-90.
23. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 2002;5:452-7.
24. Kotilinek LA, Basckai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. Reversible memory loss in mouse transgenic model of Alzheimer's disease. J Neurosci 2002;22:6331-5.
25. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000;283:1571-7.
26. Gong Y, Chang l, Viola KL, Lacor PN, Lambert MP, Finch CE, et al. Alzheimer's disease-affected brain; presence of oligomeric A( ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 2003; 100:10417-22.
27. Haass C, Selkoe DJ. Soluble protein oligomers in neurode-generation: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007;8:101-12.
28. Harper JD, Wong SS, Lieber CM, Lansbury PT Jr. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 1997;4:119-25.
29. Walsh DM, Lomakin A, Benedek GB, Condrom MM, Teplow DB. Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 1997;272:22364-72.
30. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006;440(7082):352-7.
31. Coleman P, Federoff H, Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology 2004;63:1155-62.
32. Lacor PN, Buniel MC, Chang L, Fernandez S, Gong Y, Viola KL, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004;24:10191-200.
33. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 2007;100:23-35.
34. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400:173-7.
35. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Med 2000;6:916-919.
36. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004;14:11-20.
37. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, et al. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38: 547-54.
38. Solomon B, Koppel R, Hana E, Katzav T. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer β-amyloid peptide. Proc Natl Acad Sci USA 1996;93:452-5
39. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, et al. Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nature Med 2002;8:1263-9.
40. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, et al. Self-assembly of Abeta (1-42) into globular neurotoxins. Biochemistry 2003;42:12749-60.
41. Frisardi V, Solfrizzi V, Imbimbo BP, Capurso C, D'Introno A, Colacicco AM, et al. Towards disease-modifying treatment of Alzheimer's disease: drugs targeting beta-amyloid. Curr Alzheimer Res 2009;7:40-55.
42. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem 2008;8:54-61
43. Hüll M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs 2006; 66:2075-93.
44. Christensen DD. Alzheimer's disease: progress in the development of anti-amyloid disease-modifying therapies. CNS Spectr 2007;12:113-23.